Results 31 to 40 of about 12,561 (177)

Effectiveness and safety of edoxaban in patients with atrial fibrillation:data from the Danish nationwide cohort [PDF]

, 2021
Aims: Edoxaban treatment for stroke prevention in atrial fibrillation (AF) has mainly been investigated in randomized controlled trials, and data reflecting clinical practice are limited.
Nielsen, Peter Brønnum; id_orcid, Larsen, Torben Bjerregaard, Skjøth, Flemming, Søgaard, Mette; id_orcid, Lip, Gregory Y H   +4 more
core   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux, Camm AJ, Bounameaux H   +5 more
core   +1 more source

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)

Thrombosis Journal, 2023
Background Gynecological cancer is one of the highest risk factors for cancer-associated thrombosis (CAT). Although low-molecular-weight heparin (LMWH) is recommended as an anticoagulant for treating CAT, recent studies have shown that direct oral ...
Tadashi Oride, Kenjiro Sawada, Aasa Shimizu, Yasuto Kinose, Tsuyoshi Takiuchi, Michiko Kodama, Kae Hashimoto, Eiji Kobayashi, Eiji Nakatani, Tadashi Kimura   +9 more
doaj   +1 more source

Study of weight variation and dissolution of Edoxaban split tablets in pharmacy practice [PDF]

Pharmaceutical Sciences Asia, 2022
Edoxaban is available in 60 mg, 30 mg, and 15 mg unscored film-coated tablets. Tablet splitting may be an option to reduce medication costs and reduce the country’s budget.
Mantiwee Nimworapan, Sinwisuth Sutheechai, Wanwarang Wongcharoen, Arintaya Phrommintikul, Suntara Eakanunkul   +4 more
doaj   +1 more source

Hip fractures risks in edoxaban versus warfarin users: A propensity score-matched population-based cohort study with competing risk analyses

, 2021
The three direct oral anticoagulants (DOAC), rivaroxaban, apixaban and dabigatran have been associated with lower risks of fractures compared to warfarin. However, no large scale studies have explored the associations with the newest DOAC, edoxaban, with
Hou In Chou, Oscar, Liu, Xuejin, Tai Loy Lee, Teddy, Liu, Tong, Iltaf Satti, Danish, Lee, Sharen, Zhou, Jiandong, Tse, Gary, Roever, Leonardo, Ka Chung Wai, Abraham, Zhang, Qingpeng, Chang, Carlin, Tak Wong, Wing, Chang, C, Liu, X, Liu, T, Chou, OHI, Wong, WT, Zhou, J, Lee, S, Iltaf Satti, D, Zhang, Q, Tse, G, Lee, TLT, Wai, KCA, Roever, L, Xuejin Liu, Tong Liu, Carlin Chang, Qingpeng Zhang, Wing Tak Wong, Teddy Tai Loy Lee, Oscar Hou In Chou, Leonardo Roever, Danish Iltaf Satti, Jiandong Zhou, Gary Tse, Sharen Lee, Abraham Ka Chung Wai   +38 more
core   +1 more source

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis

Medicines, 2023
Background: Edoxaban is a novel oral anticoagulant which may decrease the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).
Yapeng Wang, Li Li, Zhanlan Wei, Shan Lu, Wenxue Liu, Janghui Zhang, Junbo Feng, Dongjin Wang   +7 more
doaj   +1 more source

Edoxaban [PDF]

Reactions Weekly, 2020
  +9 more sources

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)

Thrombosis Journal, 2019
Background This study involved a sensory evaluation of edoxaban orally disintegrating (OD) tablets in patients with nonvalvular atrial fibrillation who had been receiving the existing edoxaban film-coated tablets before the study.
Takeshi Yamashita, Joji Hagii, Yoshiyuki Morishima, Takaaki Akasaka, Takuyuki Matsumoto, Tetsuya Kimura   +5 more
doaj   +1 more source

Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. [PDF]

PLoS ONE, 2014
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an imputed-placebo analysis with estimates of the proportion of warfarin effect preserved by each non
Paolo Verdecchia, Fabio Angeli, Gregory Y H Lip, Gianpaolo Reboldi   +3 more
doaj   +1 more source

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response

Physiological Reports, 2022
Chronic kidney disease (CKD) is an increasing and life‐threatening disease worldwide. Recent evidence indicates that blood coagulation factors promote renal dysfunction in CKD patients.
Lixin Fang, Koji Ohashi, Hayato Ogawa, Naoya Otaka, Hiroshi Kawanishi, Tomonobu Takikawa, Yuta Ozaki, Kunihiko Takahara, Minako Tatsumi, Mikito Takefuji, Toyoaki Murohara, Noriyuki Ouchi   +11 more
doaj   +1 more source